October 24, 2011 10:30 AM Eastern Daylight Time
WIRE)--Sanofi (EURONEXT: SAN and NYSE: SNY) announced
today the appointment of David Meeker as Chief Executive
Genzyme, a Sanofi company, effective November 1, 2011.
He will report to Christopher A. Viehbacher, Chief
Executive Officer of Sanofi, and will join the Group
Management Committee. Christopher A. Viehbacher will retain
the position of Chairman, Genzyme.
"David's commitment to employees, physicians and patients
has been a key success factor in the successful integration
of Genzyme as part of the Sanofi Group. His combination of
medical and business experience will be essential to move
Genzyme's broad portfolio of products forward and deliver
much-needed therapies to patients."
"After working closely with David over the past six months,
I am confident that he is the best person to lead Genzyme,"
said Christopher A. Viehbacher, Chief Executive Officer of
Sanofi. "David's commitment to employees, physicians and
patients has been a key success factor in the successful
integration of Genzyme as part of the Sanofi Group.His
combination of medical and business experience will be
essential to move Genzyme's broad portfolio of products
forward and deliver much-needed therapies to patients."
Under David Meeker's leadership, Genzyme will incorporate
the Rare Disease business and the Multiple Sclerosis
franchise. Previous Genzyme divisions - Renal, Biosurgery
and Oncology - have been integrated within the existing
Sanofi portfolio giving them greater global scale and
David joined Genzyme in 1994 as Medical Director to work on
the Cystic Fibrosis Gene Therapy program. Over the years he
has held key positions of increasing responsibility as he
led the development of treatments in the current rare
disease portfolio. As President of the Global Rare Disease
Business, he oversaw the global launches of Aldurazyme®,
Fabrazyme® and Myozyme®. In 2009, he was promoted to Chief
Operating Officer of Genzyme and has played an important
role in the integration since April of this year. David
received his M.D. from the University of Vermont Medical
School, and completed the Advanced Management Program at
Harvard Business School in 2000.
Sanofi, a global and diversified healthcare leader,
discovers, develops and distributes therapeutic solutions
focused on patients' needs. Sanofi has core strengths in
the field of healthcare with seven growth platforms:
diabetes solutions, human vaccines, innovative drugs, rare
diseases, consumer healthcare, emerging markets and animal
health. Sanofi is listed in Paris (EURONEXT: SAN) and in
New York (NYSE: SNY).